Skip to Content

Are you misusing IVIGs in your system?

Intravenous immune globulins (IVIGs) represent $1.7 billion in annual spend for U.S. health systems. With nine major brands and over 100 documented off-label uses, health systems need to take a critical look at standardizing use.

Download this case study to:

  • Learn how one health system saved $500K by eliminating multiple IVIG brands
  • Explore how an academic medical center stopped excessive off-label use
  • Understand why clinical evidence is the key to tackling inappropriate drug utilization